Clinical Trial Update: Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating an 18F-APN-1607 PET imaging agent in subjects with Alzheimer's-related cognitive impairment and normal cognition.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment

Drugs mentioned

• [18F]APN-1607 (APN-1607)

Snippet

Sponsor: JYAMS PET Research & Development Limited | Conditions: Subjects With Mild Cognitive Impairment (MCI) of AD, Alzheimer's Disease (AD) Dementia | Phase 3 | Status: RECRUITING